Buscopan is NOT approved for use in 5-year-old children
Do not use Buscopan (hyoscine butylbromide) in a 5-year-old child, as there is no established safety or efficacy data for this age group, and the available evidence documents serious adverse effects from overdose in young children.
Critical Age Limitation
The evidence provided does not support use of hyoscine butylbromide (Buscopan) in children under 6 years of age:
No pediatric approval exists for this age: The drug labels provided 11 refer to buspirone (an anti-anxiety medication), NOT Buscopan/hyoscine butylbromide. This appears to be a documentation error, but importantly, no FDA-approved pediatric indication for Buscopan in children under 6 years was provided.
Documented toxicity in this age group: A case report describes a 4-year-old who developed confusion, ataxia, hallucinations, hypotension, tachycardia, and QTc prolongation after accidental overdose of hyoscine hydrobromide (a related compound) 2. The authors specifically note concerns about accessibility and toxicity in young children.
Evidence in Older Children (Age 8-17)
The only pediatric efficacy study provided evaluated children aged 8-17 years for colicky abdominal pain 3. In this randomized controlled trial:
- Hyoscine butylbromide (10 mg oral) was compared to acetaminophen
- No superiority was demonstrated over acetaminophen
- Both agents provided clinically important pain reduction
- Adverse effects occurred in 27.6% with hyoscine butylbromide vs 24.3% with acetaminophen (not statistically different)
Clinical Implications
For a 5-year-old child:
- Age is below studied populations: All pediatric evidence involves children ≥8 years old
- Safety concerns are documented: Serious anticholinergic toxicity can occur in young children
- Alternative options exist: Acetaminophen showed equivalent efficacy in older children and has established pediatric dosing for age 5
Recommendation for Clinical Practice
If treating abdominal cramping/pain in a 5-year-old:
- Use acetaminophen (15 mg/kg, maximum 975 mg) as first-line therapy
- Consider other age-appropriate analgesics
- Avoid hyoscine butylbromide due to lack of safety/efficacy data in this age group
- If spasmodic pain persists, seek specialist gastroenterology consultation rather than using off-label antispasmodics
The risk-benefit ratio does not support use of Buscopan in children under 6 years of age.